Will Pfizer ($PFE) come back at AstraZeneca ($AZN)? That's been the question of the summer, especially since the U.S. Treasury Department rolled out new rules for tax-inversion deals. Now, sources are telling the Financial Times and CNBC that the collapse of AbbVie's ($ABBV) buyout of Ireland-based Shire ($SHPG) make another Pfizer bid unlikely. Unless the midterm elections go against President Obama, that is. Report | Report